NCT00003415View on ClinicalTrials.gov

Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 30, 1998

Study Completion Date

November 30, 2002

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

amifostine trihydrate

DRUG

topotecan hydrochloride

Trial Locations (1)

85724

Arizona Cancer Center, Tucson

All Listed Sponsors
lead

University of Arizona

OTHER

NCT00003415 - Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter